NewsHK
Equity inducement plans have become a common recruitment tool across the biotech sector, particularly at companies competing for clinical and scientific talent.
(Nasdaq: HURA), based in Tampa, Florida, disclosed the mechanics of one such plan in an amended filing on September 17, 2026, adding detail to a package its board had approved the week before.
The board adopted the TuHURA Biosciences, Inc. 2026 Inducement Equity Incentive Plan on September 10, reserving 5,000,000 shares of common stock at a par value of $0.001 per share for future issuance.
The plan bypasses stockholder approval, relying on Nasdaq Listing Rule 5635(c)(4), which permits inducement grants to new hires without a shareholder vote.
Keep reading